Prime Medicine, Inc. SEC filings PRME
Prime Medicine, Inc. has 298 filings in SEC EDGAR's recent list, going back to Dec 20, 2021. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 6, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Other events
|
Jul 8, 2026 | Jul 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 8, 2026 | Jun 5, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| ARS | Annual report to shareholders | Apr 23, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Apr 16, 2026 | Apr 7, 2026 |
| EFFECT | Filing | Mar 4, 2026 | — |
| S-8 | Employee stock plan registration | Mar 3, 2026 | — |
| POS AM | Filing | Mar 3, 2026 | — |
| 10-K | Annual report | Mar 3, 2026 | Dec 31, 2025 |
| POSASR | Filing | Mar 3, 2026 | — |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 3, 2026 | Mar 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| S-3ASR | Automatic shelf registration | Nov 7, 2025 | — |
| 10-Q | Quarterly report | Nov 7, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2025 | Nov 7, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2025 | Sep 8, 2025 |
| 10-Q | Quarterly report | Aug 7, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Aug 5, 2025 | Aug 1, 2025 |
| 8-K |
Current report
Material agreement
|
Jul 31, 2025 | Jul 30, 2025 |
| 424B5 | Prospectus supplement | Jul 31, 2025 | — |
| 424B5 | Prospectus supplement | Jul 30, 2025 | — |
| 8-K |
Current report
Results of operations, Other events
|
Jul 30, 2025 | Jul 30, 2025 |
| 8-K |
Current report
Officer or director change
|
Jul 15, 2025 | Jul 14, 2025 |
| DEF 14A | Proxy statement | Jul 14, 2025 | Aug 1, 2025 |
| PRE 14A | Preliminary proxy statement | Jul 2, 2025 | Aug 1, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2025 | Jun 4, 2025 |
| DEFA14A | Additional proxy material | May 19, 2025 | — |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure, Other events
|
May 19, 2025 | May 16, 2025 |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| ARS | Annual report to shareholders | Apr 22, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 22, 2025 | — |
| DEF 14A | Proxy statement | Apr 22, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 18, 2025 | Mar 18, 2025 |
| S-8 | Employee stock plan registration | Feb 28, 2025 | — |
| 10-K | Annual report | Feb 28, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 28, 2025 | Feb 28, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 13, 2025 | Jan 13, 2025 |
| EFFECT | Filing | Dec 20, 2024 | — |
| CORRESP | Letter to the SEC | Dec 18, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 17, 2024 | — |
| S-3 | Shelf registration | Dec 13, 2024 | — |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2024 | Nov 12, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 24, 2024 | Oct 24, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Sep 30, 2024 | Sep 28, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 12, 2024 | Jun 12, 2024 |
| DEFA14A | Additional proxy material | May 21, 2024 | — |
| 8-K |
Current report
Bylaw or fiscal year change
|
May 21, 2024 | May 17, 2024 |
| 10-Q | Quarterly report | May 10, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 10, 2024 | May 10, 2024 |
| ARS | Annual report to shareholders | Apr 29, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Jun 12, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 19, 2024 | Jun 12, 2024 |
| S-8 | Employee stock plan registration | Mar 1, 2024 | — |
| 10-K | Annual report | Mar 1, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 1, 2024 | Mar 1, 2024 |
| 8-K |
Current report
Material agreement
|
Feb 16, 2024 | Feb 14, 2024 |
| 424B5 | Prospectus supplement | Feb 16, 2024 | — |
| FWP | Free writing prospectus | Feb 15, 2024 | — |
| 424B5 | Prospectus supplement | Feb 14, 2024 | — |
| 8-K |
Current report
Results of operations
|
Feb 14, 2024 | Feb 14, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 8, 2024 | Jan 8, 2024 |
| 8-K |
Current report
Other events
|
Jan 5, 2024 | Jan 4, 2024 |
| 8-K |
Current report
Officer or director change
|
Jan 5, 2024 | Jan 4, 2024 |
| EFFECT | Filing | Nov 13, 2023 | — |
| CORRESP | Letter to the SEC | Nov 9, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2023 | — |
| S-3 | Shelf registration | Nov 3, 2023 | — |
| 10-Q | Quarterly report | Nov 3, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2023 | Nov 3, 2023 |
| 10-Q | Quarterly report | Aug 7, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 7, 2023 | Aug 7, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2023 | Jun 14, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
May 17, 2023 | May 17, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| DEFA14A | Additional proxy material | May 11, 2023 | — |
| 8-K |
Current report
Officer or director change
|
May 11, 2023 | May 10, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| ARS | Annual report to shareholders | Apr 28, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 14, 2023 |
| 8-K/A |
Amended current report
Results of operations
|
Mar 10, 2023 | Mar 9, 2023 |
| S-8 | Employee stock plan registration | Mar 9, 2023 | — |
| 10-K | Annual report | Mar 9, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 9, 2023 | Mar 9, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 9, 2023 | Jan 9, 2023 |
| 10-Q | Quarterly report | Nov 14, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 24, 2022 | Oct 19, 2022 |
| 424B4 | Prospectus | Oct 21, 2022 | — |
| FWP | Free writing prospectus | Oct 20, 2022 | — |
| SEC STAFF LETTER | Filing | Oct 19, 2022 | — |
| EFFECT | Filing | Oct 19, 2022 | — |
| S-1MEF | Filing | Oct 19, 2022 | — |
| S-8 | Employee stock plan registration | Oct 19, 2022 | — |
| CERT | Filing | Oct 19, 2022 | — |
| 8-A12B | Filing | Oct 17, 2022 | — |
| CORRESP | Letter to the SEC | Oct 17, 2022 | — |
| CORRESP | Letter to the SEC | Oct 17, 2022 | — |
| FWP | Free writing prospectus | Oct 17, 2022 | — |
| CORRESP | Letter to the SEC | Oct 17, 2022 | — |
| S-1/A | Amended registration statement | Oct 17, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 14, 2022 | — |
| CORRESP | Letter to the SEC | Oct 13, 2022 | — |
| S-1/A | Amended registration statement | Oct 13, 2022 | — |
| CORRESP | Letter to the SEC | Oct 7, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2022 | — |
| S-1 | Registration statement | Sep 23, 2022 | — |
| DRS/A | Filing | Aug 5, 2022 | — |
| DRS/A | Filing | May 6, 2022 | — |
| SEC STAFF LETTER | Filing | Apr 11, 2022 | — |
| DRSLTR | Filing | Apr 8, 2022 | — |
| DRS/A | Filing | Apr 8, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 30, 2022 | — |
| DRSLTR | Filing | Mar 25, 2022 | — |
| DRS/A | Filing | Mar 25, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 15, 2022 | — |
| DRSLTR | Filing | Mar 7, 2022 | — |
| DRS/A | Filing | Mar 7, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 17, 2022 | — |
| DRSLTR | Filing | Feb 4, 2022 | — |
| DRS/A | Filing | Feb 4, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 18, 2022 | — |
| DRS/A | Filing | Jan 12, 2022 | — |
| DRS | Filing | Dec 20, 2021 | — |
Showing 134 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PRME (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1894562
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.